• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
UBI
Click for more information
0.00% 12.0¢

UNIVERSAL BIOSENSORS INC. - Announcements

Market Cap $38.74M  ! watchlist Created with Sketch. Add to my watchlist

Universal Biosensors, Inc. is a biosensor company. The Company is engaged in developing... Universal Biosensors, Inc. is a biosensor company. The Company is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women’s health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
UBI Appendix 3B19/03/19
UBI Appendix 3B13/03/19
UBI FY2018 Results PresentationPRICE SENSITIVE08/03/19
UBI Resignation of CEO Rick LegleiterPRICE SENSITIVE08/03/19
UBI Change in substantial holding from CVC06/03/19
UBI FY2018 Conference Call Notification04/03/19
UBI Appendix 3B28/02/19
UBI Appendix 4G22/02/19
UBI Corporate Governance Statement22/02/19
UBI Appendix 4E and Annual Report on Form 10-K FY2018PRICE SENSITIVE22/02/19
UBI Receipt of Lump Sum Service FeesPRICE SENSITIVE18/02/19
UBI Appendix 3B18/02/19
UBI Term Sheet AgreementPRICE SENSITIVE11/02/19
UBI Appendix 4C - quarterlyPRICE SENSITIVE29/01/19
UBI Change in substantial holding08/01/19
UBI Business UpdatePRICE SENSITIVE20/12/18
UBI Appendix 3B17/12/18
UBI Appendix 3B14/12/18
UBI Notice of change of interests of substantial holder03/12/18
UBI Appendix 3B26/11/18
UBI Prepayment of LoanPRICE SENSITIVE20/11/18
UBI Appendix 3B16/11/18
UBI Q3 FY2018 resultsPRICE SENSITIVE30/10/18
UBI Appendix 4C - quarterlyPRICE SENSITIVE22/10/18
UBI Change in substantial holding from CVC11/10/18
UBI Change in substantial holding from CVC28/09/18
UBI Expiry of Unlisted Employee Options28/09/18
UBI Notice from LifeScan to buy out quarterly service feePRICE SENSITIVE26/09/18
UBI Trading HaltPRICE SENSITIVE26/09/18
UBI Change in substantial holding from CVC30/08/18
UBI Appendix 3B22/08/18
UBI H1 FY2018 Results Presentation20/08/18
UBI Half Yearly Report and AccountsPRICE SENSITIVE13/08/18
UBI H1 FY2018 Key Reporting Dates07/08/18
UBI Change in substantial holding from CVC23/07/18 download Created with Sketch. 312.52KB
UBI Appendix 4C - quarterlyPRICE SENSITIVE19/07/18 download Created with Sketch. 424.92KB
UBI Appendix 3B17/07/18 download Created with Sketch. 239.96KB
UBI Appendix 3B02/07/18 download Created with Sketch. 246.68KB
UBI Results of Meeting25/06/18 download Created with Sketch. 26.71KB
UBI CEO's AGM Address to Shareholders25/06/18 download Created with Sketch. 143.86KB
UBI Appendix 3B22/06/18 download Created with Sketch. 246.69KB
UBI Change in substantial holding18/06/18 download Created with Sketch. 707.31KB
UBI Becoming a substantial holder from CVC25/05/18 download Created with Sketch. 251.31KB
UBI Annual Report to shareholders09/05/18
UBI US SEC Form 4 Purchase of shares by R Legleiter09/05/18
UBI Becoming a substantial holder07/05/18
UBI Notice of General Meeting/Proxy Form27/04/18
UBI Q1 FY2018 resultsPRICE SENSITIVE27/04/18
UBI Appendix 4C - quarterlyPRICE SENSITIVE24/04/18
UBI Resignation of Dr Alastair Hodges23/04/18
UBI Appendix 3B13/04/18
UBI Resignation of Mr Garry Chambers13/04/18
UBI Expiry of Unlisted Options03/04/18
UBI Change of Director's Interest Notice19/03/18
UBI FY2017 Results presentation26/02/18
UBI Appendix 4G23/02/18
UBI Corporate Governance Statement23/02/18
UBI Appendix 4E and Annual Report on Form 10KPRICE SENSITIVE23/02/18
UBI FY2017 Results Conference Call19/02/18
UBI Appendix 3B06/02/18
UBI Change of Director's Interest Notice05/02/18
UBI Appendix 3B29/01/18
UBI Appendix 4C - quarterlyPRICE SENSITIVE22/01/18
UBI Expiry of Unlisted Options19/01/18
UBI Expiry of Unlisted Options04/01/18
UBI Extension of Athyrium term loan02/01/18
UBI Change in substantial holding29/12/17
UBI Appendix 3B22/12/17
UBI Revised Securities Trading Policy20/12/17
UBI Appendix 3B30/11/17
UBI Appendix 4G and Corporate Governance Statement16/11/17
UBI Aggregate Quarterly Service Fees received exceed US$45mPRICE SENSITIVE15/11/17
UBI Appendix 3B27/10/17
UBI Appendix 3B24/10/17
UBI Q3 2017 Financial Results and SEC Form 10-QPRICE SENSITIVE24/10/17
UBI Appendix 4C - quarterlyPRICE SENSITIVE23/10/17
UBI Receives $7.5M under the R&D Tax IncentivePRICE SENSITIVE16/10/17
UBI Expiry of Unlisted Options19/09/17
UBI Appendix 3B07/09/17
UBI Appendix 3B18/08/17
UBI Final Director's Interest Notice x207/08/17
UBI H1 2017 Financial results presentation07/08/17
UBI Half Yearly Report and AccountsPRICE SENSITIVE07/08/17
UBI CEO appointment, Chairman succession and Board RenewalPRICE SENSITIVE07/08/17
UBI H1 2017 Results Conference Call and Webcast26/07/17
UBI Appendix 3B18/07/17
UBI Appendix 4C - quarterlyPRICE SENSITIVE17/07/17
UBI Results of Meeting22/06/17
UBI AGM Business UpdatePRICE SENSITIVE22/06/17
UBI Chairman's address to AGM22/06/17
UBI Commencement of Xprecia Stride sales activities in USPRICE SENSITIVE08/05/17
UBI Q1 2017 Financial Results and SEC Form 10-QPRICE SENSITIVE27/04/17
UBI Appendix 4C - quarterlyPRICE SENSITIVE27/04/17
UBI Definitive Proxy Statement filed with the SEC21/04/17
UBI Appendix 3B11/04/17
UBI Release of restricted shares31/03/17
UBI 2016 Financial Year Annual Results Presentation21/03/17
UBI Annual Report to shareholders on Form 10K21/03/17
UBI FY 2016 Results Conference Call16/03/17
UBI Preliminary Proxy Statement Filed with SEC13/03/17
UBI Appendix 3B
19/03/19
UBI Appendix 3B
13/03/19
UBI FY2018 Results Presentation
08/03/19PRICE SENSITIVE
UBI Resignation of CEO Rick Legleiter
08/03/19PRICE SENSITIVE
UBI Change in substantial holding from CVC
06/03/19
UBI FY2018 Conference Call Notification
04/03/19
UBI Appendix 3B
28/02/19
UBI Appendix 4G
22/02/19
UBI Corporate Governance Statement
22/02/19
UBI Appendix 4E and Annual Report on Form 10-K FY2018
22/02/19PRICE SENSITIVE
UBI Receipt of Lump Sum Service Fees
18/02/19PRICE SENSITIVE
UBI Appendix 3B
18/02/19
UBI Term Sheet Agreement
11/02/19PRICE SENSITIVE
UBI Appendix 4C - quarterly
29/01/19PRICE SENSITIVE
UBI Change in substantial holding
08/01/19
UBI Business Update
20/12/18PRICE SENSITIVE
UBI Appendix 3B
17/12/18
UBI Appendix 3B
14/12/18
UBI Notice of change of interests of substantial holder
03/12/18
UBI Appendix 3B
26/11/18
UBI Prepayment of Loan
20/11/18PRICE SENSITIVE
UBI Appendix 3B
16/11/18
UBI Q3 FY2018 results
30/10/18PRICE SENSITIVE
UBI Appendix 4C - quarterly
22/10/18PRICE SENSITIVE
UBI Change in substantial holding from CVC
11/10/18
UBI Change in substantial holding from CVC
28/09/18
UBI Expiry of Unlisted Employee Options
28/09/18
UBI Notice from LifeScan to buy out quarterly service fee
26/09/18PRICE SENSITIVE
UBI Trading Halt
26/09/18PRICE SENSITIVE
UBI Change in substantial holding from CVC
30/08/18
UBI Appendix 3B
22/08/18
UBI H1 FY2018 Results Presentation
20/08/18
UBI Half Yearly Report and Accounts
13/08/18PRICE SENSITIVE
UBI H1 FY2018 Key Reporting Dates
07/08/18
UBI Change in substantial holding from CVC
23/07/18 download Created with Sketch. 312.52KB
UBI Appendix 4C - quarterly
19/07/18PRICE SENSITIVE download Created with Sketch. 424.92KB
UBI Appendix 3B
17/07/18 download Created with Sketch. 239.96KB
UBI Appendix 3B
02/07/18 download Created with Sketch. 246.68KB
UBI Results of Meeting
25/06/18 download Created with Sketch. 26.71KB
UBI CEO's AGM Address to Shareholders
25/06/18 download Created with Sketch. 143.86KB
UBI Appendix 3B
22/06/18 download Created with Sketch. 246.69KB
UBI Change in substantial holding
18/06/18 download Created with Sketch. 707.31KB
UBI Becoming a substantial holder from CVC
25/05/18 download Created with Sketch. 251.31KB
UBI Annual Report to shareholders
09/05/18
UBI US SEC Form 4 Purchase of shares by R Legleiter
09/05/18
UBI Becoming a substantial holder
07/05/18
UBI Notice of General Meeting/Proxy Form
27/04/18
UBI Q1 FY2018 results
27/04/18PRICE SENSITIVE
UBI Appendix 4C - quarterly
24/04/18PRICE SENSITIVE
UBI Resignation of Dr Alastair Hodges
23/04/18
UBI Appendix 3B
13/04/18
UBI Resignation of Mr Garry Chambers
13/04/18
UBI Expiry of Unlisted Options
03/04/18
UBI Change of Director's Interest Notice
19/03/18
UBI FY2017 Results presentation
26/02/18
UBI Appendix 4G
23/02/18
UBI Corporate Governance Statement
23/02/18
UBI Appendix 4E and Annual Report on Form 10K
23/02/18PRICE SENSITIVE
UBI FY2017 Results Conference Call
19/02/18
UBI Appendix 3B
06/02/18
UBI Change of Director's Interest Notice
05/02/18
UBI Appendix 3B
29/01/18
UBI Appendix 4C - quarterly
22/01/18PRICE SENSITIVE
UBI Expiry of Unlisted Options
19/01/18
UBI Expiry of Unlisted Options
04/01/18
UBI Extension of Athyrium term loan
02/01/18
UBI Change in substantial holding
29/12/17
UBI Appendix 3B
22/12/17
UBI Revised Securities Trading Policy
20/12/17
UBI Appendix 3B
30/11/17
UBI Appendix 4G and Corporate Governance Statement
16/11/17
UBI Aggregate Quarterly Service Fees received exceed US$45m
15/11/17PRICE SENSITIVE
UBI Appendix 3B
27/10/17
UBI Appendix 3B
24/10/17
UBI Q3 2017 Financial Results and SEC Form 10-Q
24/10/17PRICE SENSITIVE
UBI Appendix 4C - quarterly
23/10/17PRICE SENSITIVE
UBI Receives $7.5M under the R&D Tax Incentive
16/10/17PRICE SENSITIVE
UBI Expiry of Unlisted Options
19/09/17
UBI Appendix 3B
07/09/17
UBI Appendix 3B
18/08/17
UBI Final Director's Interest Notice x2
07/08/17
UBI H1 2017 Financial results presentation
07/08/17
UBI Half Yearly Report and Accounts
07/08/17PRICE SENSITIVE
UBI CEO appointment, Chairman succession and Board Renewal
07/08/17PRICE SENSITIVE
UBI H1 2017 Results Conference Call and Webcast
26/07/17
UBI Appendix 3B
18/07/17
UBI Appendix 4C - quarterly
17/07/17PRICE SENSITIVE
UBI Results of Meeting
22/06/17
UBI AGM Business Update
22/06/17PRICE SENSITIVE
UBI Chairman's address to AGM
22/06/17
UBI Commencement of Xprecia Stride sales activities in US
08/05/17PRICE SENSITIVE
UBI Q1 2017 Financial Results and SEC Form 10-Q
27/04/17PRICE SENSITIVE
UBI Appendix 4C - quarterly
27/04/17PRICE SENSITIVE
UBI Definitive Proxy Statement filed with the SEC
21/04/17
UBI Appendix 3B
11/04/17
UBI Release of restricted shares
31/03/17
UBI 2016 Financial Year Annual Results Presentation
21/03/17
UBI Annual Report to shareholders on Form 10K
21/03/17
UBI FY 2016 Results Conference Call
16/03/17
UBI Preliminary Proxy Statement Filed with SEC
13/03/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
12.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $38.74M
Open High Low Value Volume
12.0¢ 12.0¢ 12.0¢ $21.82K 181.9K

Buyers (Bids)

No. Vol. Price($)
3 110000 11.5¢
 

Sellers (Offers)

Price($) Vol. No.
13.0¢ 548555 3
View Market Depth
Last trade - 14.18pm 15/11/2024 (20 minute delay) ?
UBI (ASX) Chart

Top Stories

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.